Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach
- PMID: 2765444
- PMCID: PMC1041835
- DOI: 10.1136/bjo.73.8.639
Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach
Abstract
Patients with serious inflammatory Graves' ophthalmopathy should be treated with anti-inflammatory drugs or radiotherapy to prevent complications like fibrosis, while those with non-inflammatory ophthalmopathy may be treated by surgery immediately. It is often difficult, however, to distinguish inflammatory from non-inflammatory Graves' disease. We therefore present a simple clinical classification here to differentiate between these two conditions. This classification is based on the classical signs of inflammation--pain, redness, swelling, and impaired function. After two consecutive clinical examinations an 'activity score' can be determined, ranging from 0 to 10 points. In a retrospective study testing the efficacy of this classification we found that patients with an activity score of 3 or more at the beginning of therapy responded well to anti-inflammatory drugs, while those with a lower activity score mostly did not. Comparing the pretreatment activity score with the degree of enlargement of the extraocular muscles on the CT scan, we found a significant correlation between these two parameters: the higher the activity score, the more the enlargement of the muscles. We conclude that this classification facilitates the proper selection of patients for treatment.
Similar articles
-
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.Clin Endocrinol (Oxf). 1997 Jul;47(1):9-14. doi: 10.1046/j.1365-2265.1997.2331047.x. Clin Endocrinol (Oxf). 1997. PMID: 9302365 Clinical Trial.
-
Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.J Clin Endocrinol Metab. 1998 Nov;83(11):3790-4. doi: 10.1210/jcem.83.11.5274. J Clin Endocrinol Metab. 1998. PMID: 9814448 Clinical Trial.
-
[Treatment of Grave's ophthalmopathy with high doses of corticosteroids].Srp Arh Celok Lek. 2000 May-Jun;128(5-6):179-83. Srp Arh Celok Lek. 2000. PMID: 11089418 Serbian.
-
Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.Lancet Diabetes Endocrinol. 2017 Feb;5(2):134-142. doi: 10.1016/S2213-8587(16)30046-8. Epub 2016 Jun 23. Lancet Diabetes Endocrinol. 2017. PMID: 27346786 Review.
-
[Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids].Med Klin (Munich). 2004 Feb 15;99(2):71-6. doi: 10.1007/s00063-004-1014-9. Med Klin (Munich). 2004. PMID: 14963657 Review. German.
Cited by
-
Diagnostic precision in thyroid-associated ophthalmopathy using multi-center radiomics with 99mTc-DTPA SPECT/CT.Sci Rep. 2024 Oct 28;14(1):25810. doi: 10.1038/s41598-024-76018-4. Sci Rep. 2024. PMID: 39468140 Free PMC article.
-
Peribulbar injection of glucocorticoids for thyroid-associated ophthalmopathy and factors affecting therapeutic effectiveness: A retrospective cohort study of 386 cases.Exp Ther Med. 2020 Sep;20(3):2031-2038. doi: 10.3892/etm.2020.8896. Epub 2020 Jun 17. Exp Ther Med. 2020. PMID: 32782513 Free PMC article.
-
Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy.Dis Markers. 2015;2015:609593. doi: 10.1155/2015/609593. Epub 2015 May 18. Dis Markers. 2015. PMID: 26089587 Free PMC article.
-
Management of dysthyroid eye disease.Br J Ophthalmol. 1991 Apr;75(4):245-6. doi: 10.1136/bjo.75.4.245. Br J Ophthalmol. 1991. PMID: 1902375 Free PMC article. Review. No abstract available.
-
Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy.Sci Rep. 2018 Jul 17;8(1):10792. doi: 10.1038/s41598-018-29113-2. Sci Rep. 2018. PMID: 30018377 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical